**All Interactions with Zidovudine (Retrovir)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Zidovudine** | **Effect on Drug Levels** | **Effect on Zidovudine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Abacavir[68](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#68)  (ABC)(Ziagen) | 200 mg TID, 400 mg TID, 600 mg TID, 300 mg BID | 200 mg TID, 300 mg BID | Inconsistent effect across all dosing regimens | Not studied | - | - | No dose adjustment necessary |
| Abacavir[66](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#66),[67](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#67)  (ABC)(Ziagen) | 600 mg x 1 dose | 300 mg x 1 dose | No significant change | Zidovudine Cmax: decreased 20%; AUC: no significant change | - | Delayed zidovudine absorption | No dose adjustment necessary |
| Amprenavir[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#60)  (APV)(Agenerase) | 600 mg x 1 dose | 300 mg x 1 dose | No significant change | Zidovudine AUC: increased 31%; Cmax: increased 40% | - | - | No dose adjustment necessary |
| Atazanavir[106](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#106),  (ATV)(Reyataz) | 400 mg QD x 6 days | 300 mg BID with lamivudine 150 mg BID x 6 days | Not studied | No significant change | - | - | No dose adjustment necessary |
| Atovaquone[81](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#81)  (Mepron) | 750 mg Q12H | 200 mg Q8H | No significant change | Zidovudine AUC: increased 31%; clearance: decreased 24% | Increased zidovudine effects | Inhibition of glucuronidation by atovaquone | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Zidovudine** | **Effect on Drug Levels** | **Effect on Zidovudine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Buprenorphine[288](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#288)  (Suboxone)(Buprenex) | - | - | - | No significant change | - | - | No dose adjustment necessary |
| Clarithromycin[358](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#358),[81](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#81)  (Biaxin) | 500 mg BID | - | - | Zidovudine Cmax: increased 50%; AUC: no significant change | - | - | No dose adjustment necessary |
| Delavirdine[88](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#88)  (DLV)(Rescriptor) | - | - | No significant change | No significant change | - | - | No dose adjustment necessary |
| Didanosine[84](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#84),[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#19)  (ddI)(Videx) | 200 mg (buffered formulation) Q12H x 3 days | 200 mg Q8H x 3 days | No significant change | Zidovudine AUC: no significant change; Cmax: decreased 16.5% | - | - | No dose adjustment necessary |
| Efavirenz[90](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#90)  (EFV)(Sustiva) | 600 mg QD x 14 days | 300 mg Q12h x 14 days | No significant change | - | - | - | No dose adjustment necessary |
| Emtricitabine[132](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#132)  (FTC)(Emtriva) | 200 mg QD x 7 days | 300 mg BID x 7 days | No significant change | No significant change | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Zidovudine** | **Effect on Drug Levels** | **Effect on Zidovudine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Fluconazole[81](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#81)  (Diflucan)(Diflucan) | 400 mg QD | 200 mg Q8H | - | Zidovudine AUC: increased 74%; Half-life: increased 128% | Increased zidovudine effects | - | No dose adjustment necessary |
| Fluconazole[274](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#274)  (Diflucan)(Diflucan) | 400 mg QD, 200 mg QD | 500 mg QD, 250 mg QID | Fluconazole half-life: no significant change | Zidovudine half-life: increased | Increased zidovudine effects | - | No dose adjustment necessary |
| Ganciclovir[233](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#233),[81](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#81)  (Cytovene) | 1000 mg Q8H | - | No significant change | Zidovudine AUC: increased 19.5%; Cmax: increased 62% | Increased zidovudine effects | - | Avoid combination if possible |
| Indinavir[16](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#16)  (IDV)(Crixivan) | 1000 mg Q8H x 1 week | 200 mg Q8H x 1 week | No significant change | Zidovudine AUC: increased 17-36% | - | - | No dose adjustment necessary |
| LAAM[288](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#288)  (L-alpha-acetylmethadol) | - | - | - | No significant change | - | - | No dose adjustment necessary |
| Lamivudine[81](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#81)  (3TC)(Epivir) | - | - | No significant change | Zidovudine Cmax: increased 39% | Increased zidovudine effects | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Zidovudine** | **Effect on Drug Levels** | **Effect on Zidovudine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Lopinavir/ritonavir[78](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#78)  (LPV/r)(Kaletra) | - | - | Not studied | Not studied; may decrease zidovudine levels | Decreased zidovudine effects | Induction of glucuronidation by lopinavir/ritonavir | No dose adjustment necessary |
| Methadone[191](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#191)  (Dolophine)(Dolophine) | - | oral and IV | No significant effect | Zidovudine AUC: increased 29% (oral zidovudine); AUC: increased 41% (IV zidovudine); clearance: decreased 26% | - | - | No dose adjustment necessary |
| Methadone[202](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#202)  (Dolophine)(Dolophine) | - | 150 mg lamivudine/300 mg zidovudine (combination tablet) | No significant effect | - | - | - | No dose adjustment necessary |
| Methadone[81](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#81)  (Dolophine)(Dolophine) | 30 to 90 mg QD | 200 mg Q4H | No significant change | - | - | - | No dose adjustment necessary |
| Naltrexone[288](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#288)  (ReVia)(ReVia) | - | - | - | No significant change | - | - | No dose adjustment necessary |
| Nelfinavir[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#24)  (NFV)(Viracept) | 750 mg Q8H x 7-10 days | 200 mg x 1 dose | Not studied | Zidovudine AUC: decreased 35%; Cmax: decreased 31% | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Zidovudine** | **Effect on Drug Levels** | **Effect on Zidovudine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Nevirapine[95](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#95)  (NVP)(Viramune) | - | - | No significant change | - | - | - | No dose adjustment necessary |
| Phenytoin[81](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#81)  (Dilantin)(Dilantin) | 300 mg QD | 200 mg Q4H | No significant change | Zidovudine clearance: decreased 30% | - | - | No dose adjustment necessary |
| Probenecid[81](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#81)  (Benemid)(Benemid) | - | - | - | May increase zidovudine levels | Increased zidovudine effects | Inhibition of glucuronidation and/or renal zidovudine secretion | No dose adjustment necessary |
| Ribavirin[81](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#81)  (Rebetol, Virazole) | - | - | - | - | Possibly decreased zidovudine effects | In vitro antagonism | Avoid combination if possible |
| Ribavirin[236](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#236)  (Rebetol, Virazole) | 800 mg QD | 300 mg BID | - | No significant change | - | - | No dose adjustment necessary |
| Rifabutin[81](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#81)  (Mycobutin)(Mycobutin) | 300 mg QD x 7 or 14 days | - | - | Zidovudine half-life: decreased 28% | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Zidovudine** | **Effect on Drug Levels** | **Effect on Zidovudine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Rifampin[81](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#81)  (Rifampicin)(Rifadin) | 600 mg QD | 200 mg QD | - | Zidovudine AUC: decreased 48% | - | - | No dose adjustment necessary |
| Ritonavir[55](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#55),[58](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#58)  (RTV)(Norvir) | 300 mg Q6H | 200 mg Q8H | No significant change | Zidovudine Cmax: decreased 27%; AUC: decreased 26% | Decreased zidovudine effects | Unknown | No dose adjustment necessary |
| Stavudine[86](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#86)  (d4T)(Zerit) | - | - | - | - | Decreased stavudine effects | Competitive inhibition of intracellular phosphorylation of stavudine | Do not coadminister |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#154)  (TPV)(Aptivus) | 1250 mg BID with 100 mg ritonavir BID x 42 doses | 300 mg BID x 43 doses | - | Zidovudine AUC: decreased 31%; Cmax: decreased 51% | - | - | No dose adjustment necessary |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#154)  (TPV)(Aptivus) | 250 mg BID with 200 mg ritonavir BID | 300 mg BID | - | Zidovudine AUC: decreased 42%; Cmax: decreased 46% | - | - | No dose adjustment necessary |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#154)  (TPV)(Aptivus) | 500 mg BID with 100 mg ritonavir BID | 300 mg x 1 dose | Tipranavir Cmin: decreased 23% | Zidovudine AUC: 43%; Cmax: decreased 61%; Zidovudine glucuronide Cmin: increased 52% | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Zidovudine** | **Effect on Drug Levels** | **Effect on Zidovudine Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#154)  (TPV)(Aptivus) | 750 mg BID with 100 mg ritonavir BID | 300 mg BID | - | Zidovudine AUC: decreased 36%; Cmax: decreased 49% | - | - | No dose adjustment necessary |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#154)  (TPV)(Aptivus) | 750 mg BID with 200 mg ritonavir BID x 23 doses | 300 mg x 1 dose | No significant change | Zidovudine AUC: decreased 33%; Cmax: decreased 56%; Cmin: increased 25%; Zidovudine glucuronide Cmin: increased 94% | - | - | No dose adjustment necessary |
| Valproic acid[221](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#221)  (Depakote, Depakene, Depacon)(Depakene, Depakote) | - | - | - | Zidovudine AUC: increased 100% | Increased zidovudine effects | Inhibition of glucuronidation | No dose adjustment necessary |
| Valproic acid[81](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#81)  (Depakote, Depakene, Depacon)(Depakene, Depakote) | 250 mg Q8H, 500 mg Q8H | 100 mg Q8H | - | Zidovudine AUC: increased 79% | Increased zidovudine effects | Inhibition of glucuronidation | No dose adjustment necessary |
| Zalcitabine[85](http://arv.ucsf.edu/insite?page=ar-00-02&param=20&post=4#85)  (ddC)(Hivid) | - | - | No significant change | No significant change | - | - | No dose adjustment necessary |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 16: | Crixivan [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; Oct 2005. |
| 19: | Videx [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2003. |
| 24: | Viracept [package insert]. La Jolla, CA: Agouron Pharmaceuticals, Inc.; Sept 2004. |
| 55: | Norvir [package insert]. North Chicago, IL: Abbott Laboratories, 2008. |
| 58: | Cato A, Qian J, Hsu A, et al. Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998;42:1788-93. |
| 60: | Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004. |
| 66: | Ziagen [package insert]. Research Triangle Park, NC: GlaxoWellcome Inc.; Sept 2005. |
| 67: | Wang LH, Chittick GE, McDowell JA. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob Agents Chemother 1999;43:1708-15. |
| 68: | McDowell JA, Lou Y, Symonds WS, et al. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2000;44:2061-67. |
| 78: | Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; Oct 2005. |
| 81: | Retrovir [package insert]. Research Triangle Park, NC: GlaxoWellcome; Sept 2005. |
| 84: | Videx EC [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Oct 2005. |
| 85: | Hivid [package insert]. Nutley, NJ:Roche Laboratories Inc.;2001 |
| 86: | Zerit [package insert]. Princeton, NJ: Bristol-Myers Squibb Immunology; Sept 2005. |
| 88: | Rescriptor [package insert]. La Jolla, California: Agouron Pharmaceuticals, Inc; June 2001. |
| 90: | Sustiva [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Dec 2011. |
| 95: | Viramune [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005. |
| 106: | Mummaneni V, Randall D, Geraldes M, et al. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with lamivudine (3TC) and zidovudine (ZDV) in healthy subjects. [abstract #H-1713]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; Chicago, Illinois. |
| 132: | Zong J, Blum MR, Chittick G, et al. A steady-state evaluation of the potential pharmacokinetic interaction between emtricitabine and zidovudine in healthy volunteers [abstract #A-1620]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois. |
| 154: | Aptivus [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005. |
| 191: | McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects on zidovudine disposition (ACTG 262). JAIDS 1998;18:435-43. |
| 202: | Rainey PM, Friedland GH, Snidow JW, et al. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. Am J Addictions 2002;11:66-74. |
| 221: | Lertora JJ, Rege AB, Greenspan DL, et al. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1994;56:272-8. |
| 233: | Cimoch PJ, Lavelle J, Pollard R, et al. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:227-34. |
| 236: | Gries J-M, Torriani FJ, Rodriguez-Torres M, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HCV/HIV co-infection: final results of a randomized clinical study [abstract #136LB]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California. |
| 274: | Brockmeyer NH, Tillmann I, Mertins L, et al. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. Eur J Med Res 1997;2:377-83. |
| 288: | McCance-Katz EF, Rainey PM, Friedland G, et al. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict 2001;10:296-307. |
| 358: | Biaxin [package insert]. North Chicago, IL: Abbott Laboratories; 2003. |